« Sixteen New Biotech Drug Approvals in 2009 | Main | Outsourcing Competition in 2010? »
GEN just published latest report from Rodman & Renshaw on status of Biotech financing in Qtr 4. Consolidation, secondary offerings and IPO activity all picked up. The prediction is that increased IPO activity and more successful secondary offerings will be seen in 2010.
Posted by Bruce Lehr Jan 19, 2001
| | |
TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b0120a7ef2d71970b
Listed below are links to weblogs that reference Biotech Financing - State of the Industry:
The comments to this entry are closed.
Comments